This Week’s Biopharma News: New Approvals, Appeals, and AI

Datroway and Hepcludex secure notable FDA approvals, while Outlook wins its bevacizumab appeal, BioMarin reports phase 3 VOXZOGO data, and BMS partners with Anthropic

• June 2, 2026

• 5 min

• The Medicine Maker